SCHEMBL3556493

SCHEMBL3556493

CN(c1ccccn1)c1nc(Cl)cc(Cl)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
TDP1 Q9NUW8 2/20 0.41
CHRM2 P08172 2/20 0.39
ADRA2A P08913 2/20 0.39
DRD1 P21728 2/20 0.39
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
ADRA1A P35348 2/20 0.39
SLC6A3 Q01959 2/20 0.39
KCNH2 Q12809 2/20 0.39
CYP1A2 P05177 1/20 0.39
CHRM1 P11229 1/20 0.39
TSHR P16473 1/20 0.39
OPRM1 P35372 1/20 0.39
DRD3 P35462 1/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 1/20 0.38
PTK2 Q05397 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25687569 0.86 CYP2D6 (0.42) CYP2D6CYP2C19TDP1CHRM2ADRA2A
SCHEMBL3560362 0.80 CYP2D6 (0.40) CYP2D6CYP2C19TDP1CHRM2ADRA2A
SCHEMBL3552324 0.79 KMT2A (0.47) CYP2D6CYP1A2TSHRKDM4EALDH1A1
SCHEMBL231127 0.77 CYP2D6 (0.57) CYP2D6CYP2C19TDP1CHRM2ADRA2A
Methane SCHEMBL28533749 0.75 CYP2D6 (0.55) CYP2D6CYP2C19CHRM2ADRA2ADRD1
Hydrochloric Acid SCHEMBL6775520 0.75 CYP2D6 (0.55) CYP2D6CYP2C19CHRM2ADRA2ADRD1
SCHEMBL3987071 0.74 CYP2D6 (0.43) CYP2D6CYP2C19TDP1CHRM2ADRA2A
SCHEMBL4904986 0.74 CYP2D6 (0.50) CYP2D6CYP2C19TDP1CHRM2ADRA2A
SCHEMBL28358475 0.71 CYP2D6 (0.51) CYP2D6CYP2C19CHRM2ADRA2ADRD1
SCHEMBL4468554 0.71 KDM4E (0.50) CYP2D6CYP2C19TDP1CYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7696204-B2 Pharmaceutical compounds LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2010-04-13 US disclosed
US-20090042884-A1 Pharmaceutical Compounds F.HOFFMANN-LA ROCHE AG (CH) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042884-A1 Pharmaceutical Compounds PIK3CA, JAK1, PIK3R1 CYP2D6 874/4885CYP2C19 347/4885TDP1 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.